Cerebral Torque®
  1. Home
  2. Research
Research summary

Does Atogepant (Qulipta) Keep Working After the First Month? What Two Trials Found

Among people whose migraine days fell by half in the first month on atogepant (Qulipta), most kept that response through month 3, and most month-4 responders still had it at 1 year.

Does Atogepant (Qulipta) Keep Working After the First Month? What Two Trials Found
Study at a glance
Type of studyRandomized trial
Who was studied151 people
Bottom line. Among people whose migraine days fell by half in the first month on atogepant (Qulipta), most kept that response through month 3, and most month-4 responders still had it at 1 year.
On this pageJump to a section7
  1. The Question Behind This Analysis
  2. The Two Trials Behind the Data
  3. How Sustained Response Was Measured
  4. What the Analysis Found
  5. Reading the Numbers
  6. What This Means If You Take Atogepant
  7. References

The Question Behind This Analysis

Most migraine prevention trials report an average: how many monthly migraine days a group lost across 12 weeks. That number cannot tell you something many patients want to know after a good first month on a new preventive: will this last, or was it a lucky stretch?

A new analysis in Cephalalgia looked at that question for atogepant (Qulipta), a daily pill that blocks the CGRP receptor. The authors went back to two completed randomized controlled trials, ELEVATE and PROGRESS, plus the long-term extension study that followed them, and asked how many people who responded early were still responding later.

If you want the background on atogepant first, our overview of the atogepant trial data covers how much it lowers migraine days compared with placebo.

The Two Trials Behind the Data

Both trials tested atogepant 60 mg once daily against placebo for 12 weeks, and both were funded by AbbVie, the company that makes atogepant.

Trial Who enrolled Main result for atogepant (Qulipta) 60 mg
ELEVATE Adults with episodic migraine whose migraine had not responded to, or who could not tolerate, 2 to 4 classes of conventional oral preventives Monthly migraine days fell by 4.2 on atogepant (Qulipta) vs 1.9 on placebo across 12 weeks
PROGRESS Adults with chronic migraine, averaging about 19 migraine days a month at the start Monthly migraine days fell by 6.9 on atogepant (Qulipta) 60 mg vs 5.1 on placebo across 12 weeks
Open-label extension People who finished ELEVATE or PROGRESS and continued into a longer study where everyone took atogepant (Qulipta) Interim 12-month data used for the long-term part of this analysis

Not sure whether your own pattern counts as episodic or chronic? The chronic migraine calculator sorts that out from your headache and migraine days.

How Sustained Response Was Measured

This was a post-hoc analysis, meaning the question was asked after the trials were finished rather than planned in advance. It used the atogepant 60 mg groups: 151 people from ELEVATE and 256 from PROGRESS in the main trials.

Two Different Yardsticks

In the 12-week trials: a person counted as an early responder if their migraine days dropped by at least 50% in month 1 compared with their baseline. Their response counted as sustained only if they stayed at or above that level in both month 2 and month 3.

In the extension study: early response was measured at month 4, and sustained response meant still meeting that level at month 12. That compares two single months, which is a looser test than the back-to-back months used in the trials.

The authors also looked at stricter thresholds, a 75% drop and a 100% drop (no migraine days at all). A 50% drop is the usual responder rate cutoff in prevention trials, so it is the main focus here.

What the Analysis Found

61.3%
ELEVATE, Months 1 to 3
49 of 80 early responders kept a 50% or greater drop in both months 2 and 3
74.2%
PROGRESS, Months 1 to 3
69 of 93 early responders kept a 50% or greater drop in both months 2 and 3
83.4%
ELEVATE Group, Month 4 to 12
121 of 145 month-4 responders still had a 50% or greater drop at month 12
88.5%
PROGRESS Group, Month 4 to 12
131 of 148 month-4 responders still had a 50% or greater drop at month 12

Inside the 12-week trials

In ELEVATE, 80 of the 151 people on atogepant (about 53%) had their migraine days cut in half during month 1. Of those, 61.3% held that response through both of the next two months. In PROGRESS, 93 of 256 (about 36%) responded in month 1, and 74.2% of them held on through months 2 and 3.

Put the other way, roughly 4 in 10 early responders in ELEVATE and 1 in 4 in PROGRESS dipped below the 50% mark in month 2 or month 3. That does not mean the drug stopped working for them. Migraine days naturally rise and fall from month to month, and a single heavier month can push someone under the line.

Over the first year

In the extension study, 145 of 240 people from the ELEVATE side and 148 of 284 from the PROGRESS side had a 50% or greater drop at month 4. At month 12, 83.4% and 88.5% of them still did. The authors report that results at the 75% and 100% thresholds followed the same pattern.

Reading the Numbers

The figures reported are for people taking atogepant (Qulipta) 60 mg. On their own, they do not show how much of the steadiness comes from the drug itself rather than the natural ups and downs of migraine, or from regression to the mean, where very high starting counts tend to drift lower over time.

The extension study was open-label, so everyone knew they were taking atogepant. Long extensions also tend to keep the people who are doing well, since those who are not helped often leave. That kind of loss to follow-up can make long-term response rates look higher than they would in everyday care.

The month-12 figures also check a single month, while the trial figures required two good months in a row. The higher numbers in the extension partly reflect that easier test, not only a longer time on treatment.

Funding and Authorship

ELEVATE, PROGRESS, and the extension were funded by AbbVie, and several authors of this analysis are AbbVie employees. That is common for drug trials, and it is part of the context when reading a post-hoc look at company data.

What This Means If You Take Atogepant

For people who see a clear drop in migraine days during the first month on atogepant (Qulipta), these results are encouraging. Most early responders in both trials kept that response over the following months, and most people responding at month 4 were still responding at 1 year.

A rough month after a good start is common and does not by itself mean the drug has failed. Tracking migraine days over several months gives a fairer picture than any single month. The preventive response calculator turns your before and after counts into a percent reduction, and the printable appointment summary sheet helps you bring those numbers to your physician.

This analysis does not answer what happens to people who do not respond in month 1. For the CGRP antibody injections, other research has found that some people only respond after several months, as covered in our article on super-responders and when to expect results. Whether the same holds for atogepant was outside the scope of this paper.

Staying on a preventive is its own challenge. A large review of real-world use found that most people who stop a CGRP-targeting drug do so in the first six months, mainly because it did not work well enough, which we cover in how long people stay on anti-CGRP drugs. For how atogepant compares with an older pill on tolerability, see our write-up of the TEMPLE trial against topiramate (Topamax).

Key Takeaways
  • Of people whose migraine days fell by half in month 1 on atogepant (Qulipta), 61.3% in ELEVATE and 74.2% in PROGRESS kept that level through months 2 and 3.
  • In the extension study, 83.4% and 88.5% of people responding at month 4 were still responding at month 12.
  • One heavier month after a good start is common and does not by itself mean the drug stopped working.
  • This was a post-hoc, company-funded analysis, and the long-term data come from an open-label study without placebo.
  • The analysis does not address people who did not respond in the first month.
Important Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment. Do not start, stop, or switch a migraine preventive without talking to your physician. Individual responses to treatment vary.

References

  1. Cho SJ, Friedman DI, Chalermpalanupap N, et al. Sustained response to atogepant in episodic and chronic migraine: Post-hoc analyses of ELEVATE and PROGRESS, and their open-label extension. Cephalalgia. 2026;46(11):3331024261499722. doi:10.1177/03331024261499722.
  2. Tassorelli C, Nagy K, Pozo-Rosich P, et al. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial. The Lancet Neurology. 2024;23(4):382-392. doi:10.1016/S1474-4422(24)00025-5.
  3. Pozo-Rosich P, Ailani J, Ashina M, et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2023;402(10404):775-785. doi:10.1016/S0140-6736(23)01049-8.
CROWN cooling rollerA cold that builds. Lavender-free and third-party tested.See it on Amazon
Unraveling MigraineThe full evidence-based reference, 3rd edition.See it on Amazon
Cerebral Torque
About the author

Cerebral Torque

Founder of Cerebral Torque and author of Unraveling Migraine, with a medical background. Trained in computational and cellular neuroscience, with research using Hodgkin-Huxley modeling and clamp electrophysiology to study how neurons respond to rhythmic input. Now focused on migraine medicine and education, and has produced CME for clinicians on hormone therapy, migraine, and HRT delivery.

More about the author

This article is for education and is not medical advice. Talk with your own clinician before starting, stopping or changing any treatment.

Enter to openArrow keys to moveEsc to close

You've got this.

This screen is dimmed on purpose. A few things that help most people right now.

  1. 1
    Treat it early. Take your usual acute medicine now, at the dose your clinician gave you. Waiting usually makes it work less well.
  2. 2
    Cut the input. Dim the lights, lower the sound, step away from screens if you can.
  3. 3
    Cold and water. Something cold on the forehead or the back of the neck, and a few sips of water.
  4. 4
    Slow your breathing. Five slow minutes can take the edge off the stress response.

Get emergency care now if this is the worst headache of your life, came on like a thunderclap, or comes with new weakness, numbness, trouble speaking, confusion, fever with a stiff neck, or follows a head injury.